Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zactima vandetanib: Completed Phase III enrollment

AZN completed enrollment of 1,150 patients in the double-blind, international Phase III ZEST

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE